Our research reveals low awareness of DKA and ketone testing among type 2 diabetes patients on SGLT2 inhibitors, highlighting urgent education needs.
Our research finds that 37% of people with diabetes report poor quality sleep, and about half suffer from restless sleep or have trouble staying asleep.
Our latest Diabetes Drug Insights study follows a group of more than n=3,000 people with type 2 diabetes in the USA from 2018 to 2024.
